LESS CONVERSION TO AD AND FEWER NEUROFIBRILLARY TANGLES IN MCI PATIENTS TAKING CERTAIN ANTIHYPERTENSIVES

Whitney Wharton,Liping Zhao,Kyle Steenland,Marla Gearing,Felicia C. Goldstein

DOI: https://doi.org/10.1016/j.jalz.2017.06.1906

2017-01-01

Alzheimer s & Dementia

Abstract:With the projected increase in Alzheimer's disease (AD) prevalence, repurposing existing drugs generally recognized as safe, and show promise in AD studies, shortens the time to provide urgently needed treatment options. The renin-angiotensin system (RAS) regulates blood pressure, fluid homeostasis, and has been implicated in memory consolidation. Research suggests that antihypertensives that act via the RAS, may decrease AD risk, possibly via Aβ and/or tau. We previously reported that individuals taking RAS acting medications (ACE-Is or A2RBs), particularly those that are centrally acting, show slower cognitive decline and are less likely to progress from mild cognitive impairment (MCI) to AD over three years. However, the potential mechanism was unclear, due to the absence of neuropathological findings on these individuals. Here we test the hypothesis that individuals taking RAS acting antihypertensives may exhibit slower clinical disease progression and less AD related neuropathology than individuals taking non-RAS acting antihypertensives. Participants were older (M=83.1 years), 32% male, well educated (M=15.7 years) and 9.2% identified as Black. Males comprised a larger proportion of RAS users vs non-users (45% vs 20% for RAS users vs. non-RAS users, respectively). Groups did not differ in percent of ApoE4 positive individuals (28%) or Baseline MMSE score (M=26). While there were no group differences in blood pressure (M=138/72 mmHg), HDL (M=59mg/dL) or LDL (M=101 mg/dL), RAS users were more likely to be diabetic than non-RAS users (p=.01). Participants with MCI at Baseline who were taking a RAS medication were less likely to progress to AD than non-RAS users (p=.02). There were no group differences in brain weight, amyloid level, diffuse plaques, or NIA Reagan, Braak or CERAD scores. However, individuals taking RAS acting medications exhibited significantly fewer neurofibrillary tangles (NFT) than non-RAS users in brain regions including the hippocampal CA1 region (p